Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q1 EPS

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q1 EPS of ($0.12), in-line with the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c